Search

Your search keyword '"Metser U"' showing total 300 results
Start Over Author "Metser U"
300 results on '"Metser U"'

13. Effect of 18F-DCFPyL PET/CT (=PSMA PET) on the management of patients with suspected limited residual/recurrent disease following radical prostatectomy: Results of a prospective, multicenter registry trial

Author

Chin, J., primary, Metser, U., additional, Zukotynski, K., additional, Mak, V., additional, Langer, D., additional, Maccrostie, P., additional, Finelli, A., additional, Kapoor, A., additional, Lavallee, L., additional, Klotz, L., additional, Hagerty, M., additional, Hildebrand, C., additional, and Bauman, G., additional

Published
2022
Full Text
View/download PDF

14. Chemoradiation With or Without Metformin in Locally Advanced Cervical Cancer: Phase II Randomized Trial

Author

Han, K., primary, Fyles, T.W., additional, Shek, T., additional, Croke, J.M., additional, Dhani, N., additional, D'Souza, D.P., additional, Lee, T.Y., additional, Chaudary, N., additional, Cairns, R., additional, Pintilie, M., additional, Vines, D., additional, Jaffray, D.A., additional, Metser, U., additional, Milosevic, M., additional, and Koritzinsky, M., additional

Published
2021
Full Text
View/download PDF

16. IMPACT OF DIFFERENT INDUCTION REGIMENS ON THE OUTCOME OF PRIMARY MEDIASTINAL B CELL LYMPHOMA IN THE PROSPECTIVE IELSG 37 TRIAL

Author

Martelli, M., primary, Zucca, E., additional, Botto, B., additional, Kryachok, I., additional, Ceriani, L., additional, Balzarotti, M., additional, Tucci, A., additional, Cabras, M. G., additional, Zilioli, V. R., additional, Rusconi, C., additional, Angrilli, F., additional, Arcaini, L., additional, Iwanicka, A. Dabrowska, additional, Ferreri, A.J.M., additional, Merli, F., additional, Zhao, W., additional, Hodgson, D., additional, Ionescu, C., additional, Fosså, A., additional, Cwynarski, K., additional, Mikhaeel, G., additional, Jerkeman, M., additional, Janikova, A., additional, Hüttmann, A., additional, Ciccone, G., additional, Metser, U., additional, Barrington, S., additional, Malkowski, B., additional, Versari, A., additional, Esposito, F., additional, Cozens, K., additional, Ielmini, N., additional, Ricardi, R., additional, Cavalli, F., additional, Johnson, P., additional, and Davies, A., additional

Published
2021
Full Text
View/download PDF

22. Preliminary Results of a Two Stage Phase II Study of 18F-DCFPyL PET-MR for Enabling Oligometastases Ablative Therapy in Subclinical Prostate Cancer

Author

Glicksman, R., primary, Metser, U., additional, Vines, D., additional, Chan, R., additional, Valliant, J., additional, Chung, P., additional, Gospodarowicz, M.K., additional, Bayley, A.J., additional, Catton, C.N., additional, Warde, P.R., additional, Helou, J., additional, Lalani, N., additional, Green, D., additional, Perlis, N., additional, Fleshner, N.E., additional, Hamilton, R.J., additional, Zlotta, A., additional, Finelli, A., additional, Jaffray, D.A., additional, and Berlin, A., additional

Published
2019
Full Text
View/download PDF

23. Quantifying Renal And Tumor Doses with Individualized Dosimetry In 177Lu DOTATATE Therapy – What Difference Does It Make?

Author

Wong, R., primary, Laidley, D., additional, Myrehaug, S.D., additional, Brierley, J., additional, Juergens, R., additional, Yeung, I.W.T., additional, Breen, S., additional, Driscoll, B., additional, Shessel, A., additional, Farncombe, T., additional, Zukotynski, K., additional, Stodilka, R., additional, Caldwell, C.B., additional, Liu, Z., additional, Valliant, J., additional, McCann, J., additional, Metser, U., additional, Mohan, R., additional, Beauregard, J.M., additional, and Jaffray, D.A., additional

Published
2019
Full Text
View/download PDF

27. Étude prospective multicentrique comparant l’IRM multiparamétrique (IRM-mp), la 18f-fluorocholine (fch) et la 68ga-psma tep/tdm chez des patients candidats à la radiothérapie de rattrapage après prostatectomie radicale et avec imagerie conventionnelle normale

Author

Pouliot, F., primary, Metser, U., additional, Bauman, G., additional, Weickhardt, A., additional, Davis, I., additional, Davies, R., additional, Punwani, S., additional, Chua, S., additional, Scott, A., additional, and Emmet, L., additional

Published
2018
Full Text
View/download PDF

31. Evaluation of a predictive radiomics signature for response to immune checkpoint inhibitors (ICIs)

Author

Prawira, A., primary, Stundzia, A.B., additional, Dufort, P., additional, Halankar, J., additional, Paravasthu, D.M., additional, Spreafico, A., additional, Hansen, A.R., additional, Abdul Razak, A.R., additional, Bedard, P.L., additional, Butler, M., additional, Lheureux, S., additional, Oza, A.M., additional, Jang, R.W., additional, Suta, K.M., additional, Boross-Harmer, S., additional, Cipollone, J., additional, Chow, H., additional, Metser, U., additional, and Siu, L.L., additional

Published
2017
Full Text
View/download PDF

32. 18F-Fluorodeoxyglucose positron-emission tomography for the investigation of malignancy in patients with suspected paraneoplastic neurologic syndromes and negative or indeterminate conventional imaging: a retrospective analysis of the Ontario PET Access Program, with systematic review and meta-analysis.

Author

Harlos, C., Metser, U., Poon, R., MacCrostie, P., and Mason, W.

Subjects
*PARANEOPLASTIC syndromes, *IMAGE analysis, *TOMOGRAPHY, *COMPUTED tomography
Abstract

Objective Paraneoplastic neurologic syndrome (PNS) is a rare condition indirectly caused by an underlying malignancy. In many cases, the malignancy is occult at the time of the PNS diagnosis, and the optimal diagnostic modality to detect the underlying tumour is unclear. In the present study, we aimed to assess the utility of 18F-fluorodeoxyglucose positron-emission tomography (FDG-PET) or pet integrated with computed tomography (PET/CT) in the investigation of these patients. Methods We retrospectively analyzed data from the PET Access Program (PAP) database in the province of Ontario to identify patients who underwent FDG-PET/CT imaging as part of a workup for PNS. In all patients, prior conventional imaging was negative or indeterminate. To determine the diagnostic accuracy of FDG-PET/CT, data about demographics, presenting symptoms, and biochemical and radiologic workup, including FDG-PET/CT imaging results, were compared with data collected by the Ontario Cancer Registry (OCR). A systematic review of the literature and meta-analysis using our study inclusion criteria were performed for studies of FDG-PET accuracy. Results Of 29 patients identified in the pap database, 9 had FDG-PET/CT results suspicious for malignancy. When correlated with data from the OCR, 5 FDG-PET/CT results were informative, resulting in a detection rate of 17%. Local sensitivity and specificity were 0.83 and 0.83 respectively. Two studies meeting our criteria were identified in the literature. The pooled sensitivity and specificity from the literature and local data were 0.88 and 0.90 respectively. Conclusions When investigating for underlying malignancy in patients with suspected PNS and negative conventional imaging, pet has high sensitivity and specificity. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

34. Prospective Study of Dynamic Contrast-Enhanced MRI, Diffusion-Weighted MRI, and FDG Positron Emission Tomography Imaging in Brachytherapy for Cervix Cancer

Author

Han, K., primary, Croke, J.M., additional, Metser, U., additional, Foltz, W.D., additional, Xie, J., additional, Shek, T., additional, Driscoll, B., additional, Menard, C., additional, Vines, D., additional, Coolens, C., additional, Simeonov, A., additional, Beiki-Ardakani, A., additional, Leung, E.W., additional, Levin, W., additional, Fyles, T.W., additional, and Milosevic, M., additional

Published
2016
Full Text
View/download PDF

35. Development of a predictive radiomics signature for response to immune checkpoint inhibitors (ICIs) in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (RM-SCCHN)

Author

Prawira, A., primary, Dufort, P., additional, Halankar, J., additional, Paravasthu, D.M., additional, Hansen, A., additional, Spreafico, A., additional, Razak, A.R. Abdul, additional, Chen, E., additional, Jang, R.W., additional, Metser, U., additional, and Siu, L.L., additional

Published
2016
Full Text
View/download PDF

44. Pilot study on 18F-FDG PET/CT for detection of inflammatory changes in blood-induced knee arthropathy in a rabbit model.

Author

Shammas, A., Doria, A. S., Amirabadi, A., Gahunia, H., Jong, R., Charron, M., Moineddin, R., and Metser, U.

Subjects
KNEE diseases, JOINT diseases, FLUORODEOXYGLUCOSE F18, POSITRON emission tomography, LABORATORY rabbits, PILOT projects
Abstract

Rationale 18F- FDG- PET/ CT has a potential role in the early detection of haemophilic arthritis, at a time when treatment may still avoid further joint degeneration. The purposes of this pilot study were to determine the ability of 18F- FDG- PET/ CT to detect inflammatory changes associated with blood-induced arthropathy in knees of a rabbit model. Methods Ten juvenile rabbits were imaged at baseline and weeks 5 and 17 post intraarticular autologous blood injections ( ABI). Five rabbits in group 1 (G1) had ABI into the same knee joint every 2 weeks (total, eight injections). Five rabbits in group 2 (G2) had only two injections into the same knee, at weeks 5 and 17. Images were assessed visually and semi-quantitatively by measuring maximal standardized uptake values ( SUVmax) and standardized uptake ratio ( SUR = SUVmax in affected knee/ SUVmax in non-affected knee). Results More rabbits in G1 than G2 presented with positive chronic inflammatory synovial scores at week 17. Mean iron staining scores in injected knees were greater for G1 than for G2 ( P = 0.049). No increased uptake was identified in the injected knees in any of the rabbits at baseline or at week 5. At week 17, all G1 rabbits demonstrated increased uptake in their affected knees with higher mean SUVmax (1.5) than normal knees (1.0) ( P < 0.02). None of the G2 rabbits showed asymmetric increased uptake. The SUR of G1 was higher at week 17 compared to baseline ( P < 0.01) and week 5 ( P < 0.01). The SUR at week 17 was higher for G1 than for G2 (1.13) rabbits ( P < 0.01). Conclusion 18F- FDG- PET is able to detect the inflammatory changes associated with haemophilic arthropathy in this experimental model. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

45. Intraoperative lymph node evaluation using 18F-FDG and a hand-held gamma probe in endometrial cancer surgery - a pilot study.

Author

Metser, U., McVey, R., Ferguson, S. E., Halankar, J., and Bernardini, M. Q.

Subjects
*FLUORODEOXYGLUCOSE F18, *TREATMENT of endometrial cancer, *RADIATION exposure, *LYMPH nodes, *CLINICAL trials
Abstract

Purpose: The purpose of this pilot study was to assess feasibility, safety, and accuracy of detection of metastatic nodes intraoperatively with a hand-held gamma (PET) probe after administration of 18F-FDG in patients with high risk endometrial cancer (EC). Materials and Methods: This is a prospective, cohort study. Twenty-two patients with clinical Stage I or II EC with high-risk histologic subtypes who were candidates for open surgical intervention were screened for the study. After screening, there were seven study patients (mean age: 64; range: 53-77) who were eligible for the study. In the entire cohort, there were 61 nodal stations that were assessed with a gamma counter intraoperatively, in vivo and again after removal of the node. All adverse events were recorded and operating room staff was monitored for radiation exposure. Resected nodes underwent histological assessment as per routine clinical practice. Results: Range of maximal counts per second recorded in vivo and ex vivo were 0-86 and 0-17, respectively. Of all the nodes examined, one node was positive for metastatic disease; however, intraoperatively the lymph node readings were not higher than other lymph node basins assessed in same patient. No adverse events were recorded. The surgeons recorded the maximum average radiation exposure of all healthcare personnel with an average exposure of 0.08 mSV per case (range, 0.06-0.15). Conclusion: Use of hand-held gamma probe for intraoperative staging of patients with high risk EC is feasible, safe, and radiation exposure levels for all members of the healthcare team were within radiation safety guidelines. However, its use for detection of lymph node metastases needs further evaluation. [ABSTRACT FROM AUTHOR]

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results